Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of Helicobacter pylori: Randomized ERADICATE Hp Trial

Due to increasing resistance to commonly used antibiotics, the World Health Organization and Food and Drug Administration have advocated the development of new therapeutic regimens for Helicobacter pylori (H. pylori). This phase three, double-blind study (ERADICATE Hp) randomized (2:1) treatment-naï...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalfus, Ira N., Graham, David Y., Riff, Dennis S., Panas, Raymond M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600817/
https://www.ncbi.nlm.nih.gov/pubmed/33050205
http://dx.doi.org/10.3390/antibiotics9100685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600817/
https://www.ncbi.nlm.nih.gov/pubmed/33050205
http://dx.doi.org/10.3390/antibiotics9100685

Ejemplares similares